In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 23_Supplement ( 2015-12-01), p. B39-B39
Abstract:
Heterogeneity is a hallmark of glioblastoma with intratumoral heterogeneity contributing to variability in responses and resistance to standard treatments. DNA repair mechanisms are key elements involved in the response to temozolomide with epigenetic silencing of the O6-methylguanine methyltransferase (MGMT) promoter being a predictive biomarker for temozolomide response. However, response to temozolomide is highly variable and not always predicted by MGMT promoter methylation status. The mismatch repair (MMR) and base excision repair (BER) pathways have also been shown to be involved in treatment response with aberrations in these pathways leading to chemo-resistance and poor response to therapy. Thus changes in these pathways may confer resistance to temozolomide which is independent of MGMT methylation. Further, intratumoral heterogeneity in these pathways may also exacerbate resistance leading to worse outcomes. This study investigated intratumoral heterogeneity in glioblastoma with a particular focus on the DNA repair pathways. The cohort comprised 14 cases of glioblastoma with 2 - 6 tumor tissue biopsies (5-10mm3) per case resected from regions at least 1cm apart. Classification of transcriptional subtype was performed by gene expression profiling (Fluidigm, Taqman assays). Pyrosequencing was used to identify MGMT promoter methylation. Expression of MMR and BER genes was determined using qRT-PCR and Taqman assays and deep sequencing of these genes was performed using the MiSeq Illumina platform and Avadis NGS software. Gene expression profiling using two different limited gene-sets classified tumor specimens into the 3 major transcriptional subtypes, proneural, classical and mesenchymal, with strong concordance. These clustering techniques were then applied to tumor biopsies from the same individual. Transcriptional intratumoral heterogeneity defined as biopsies from the same individual being classified into different subtypes was identified in 40% of the patients. Intratumoral heterogeneity was also identified in the DNA repair pathways. Variability in MGMT methylation status was found in 14% of cases. In each case the percentage methylation varied up to 4-fold and the methylation status was independent of transcriptional classification. Intratumoral variation in the expression of the MMR genes MSH2 and PMS2 was identified in 15% and 20% of cases respectively and in 50% and 30% of cases for the BER genes PARP1 and APEX1. Significant heterogeneity within specimens was not identified for MMR genes MSH6 or MLH1. Targeted next generation sequencing of these 6 genes confirmed the presence of intratumoral heterogeneity at the mutation level. Up to 80 sequence variants were identified in each specimen, with 35 – 56 variants common across all specimens from a case, up to 20 shared between at least 2 specimens in a case and between 1 and 37 unique to each specimen within a case. This study identified intratumoral heterogeneity of DNA repair pathways in glioblastomas, at the genomic, transcriptional and mutational levels. These pathways have roles in the responsiveness of glioblastomas to temozolomide. As such, intratumoral heterogeneity may confound patient management. Therefore, these results highlight the importance of assessing results from multiple tumor biopsies in order to correctly manage glioblastoma patients and their treatment. Citation Format: Nicole R. Parker, Amanda L. Hudson, Peter Khong, Jonathon F. Parkinson, Rowan Ikin, Zhangkai Jason Cheng, Fatemeh Vafaee, Helen R. Wheeler, Viive M. Howell. Intratumoral heterogeneity of DNA repair pathways in glioblastoma. [abstract]. In: Proceedings of the AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2015;75(23 Suppl):Abstract nr B39.
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.BRAIN15-B39
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2015
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Permalink
